Israel Biotech Fund
Dr. Sidransky is a renowned oncologist, research scientist, and Professor of Oncology and Cellular & Molecular Medicine at John Hopkins University and Hospital. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: ONCM), a genetic testing company that was sold to Gene Logic in 1998, and Response Genetics (NASDAQ:
This person is not in any offices
Israel Biotech Fund
Israel Biotech Fund seeks high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Their key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide their portfolio companies with hands-on guidance and support.